Ultrabol 150
Overview
Ultrabol 150 British Dragon is a three-compound injectable cutting blend delivering 150 mg/ml in a 10 ml vial — 1,500 mg total. Each millilitre contains 50 mg drostanolone propionate (masteron), 50 mg testosterone propionate, and 50 mg trenbolone acetate. All three active substances carry short-chain esters (propionate or acetate), giving the blend a fast onset profile with EOD injection scheduling and a 3–5 day post-cycle clearance window before PCT. The combination covers three distinct mechanisms in a single pre-calibrated injection: testosterone propionate provides the androgenic base and muscle-protective hormone environment; drostanolone propionate contributes hardening, anti-estrogenic tissue activity, and SHBG competition; trenbolone acetate delivers high-affinity androgen receptor stimulation, nutrient partitioning, and vascularity. Together, this is the classic pre-contest cutting trinity used across competitive bodybuilding, condensed into one compound at a matched 1:1:1 ester-aligned ratio. steroidwarehouse.com carries Ultrabol 150 BD as part of the full British Dragon injectable lineup for athletes running structured pre-contest and recomposition cycles.
About the Compound
The three components of Ultrabol 150 BD work through complementary mechanisms that make the combination more effective for pre-contest preparation than any single constituent alone. Testosterone propionate provides the androgenic hormone base: it maintains libido, mood, and nitrogen retention while the suppressive effects of trenbolone eliminate endogenous testosterone production. At 50 mg/ml (175 mg/week at 1 ml EOD), the testosterone dose is deliberately moderate — sufficient to maintain physiological androgen levels and protect lean tissue without contributing significant estrogenic load. Drostanolone propionate is a 5-alpha-reduced DHT derivative that does not aromatize and actively competes with estrogen at the tissue level; it reduces the effective estrogenic influence of the testosterone component, provides cosmetic hardening and density at low body fat, and binds SHBG to increase the free fraction of circulating testosterone. Trenbolone acetate binds the androgen receptor with approximately five times the affinity of testosterone, producing potent muscle-protective and nutrient-partitioning effects without any estrogen conversion: it drives protein synthesis and nitrogen retention while simultaneously directing available nutrients away from adipose storage.
Because all three esters are short-chain (propionate for masteron and testosterone, acetate for trenbolone), Ultrabol 150 BD reaches active blood levels within 24–48 hours of the first injection and fully clears within 5–7 days of the last. This fast-clearance profile is the defining operational advantage of a short-ester cutting blend versus long-ester equivalents: PCT can begin just 3–5 days post-last-injection, the compound can be stopped quickly if side effects develop, and body composition changes during the cycle can be assessed without weeks of ester clearance delay.
What It Does
- Hardness, density, and cosmetic conditioning from the masteron fraction: drostanolone propionate produces the dry, striated, vascular appearance associated with pre-contest preparation by reducing subcutaneous water retention, competing with estrogen at tissue level, and amplifying the visual impact of low body fat; this effect is body-fat dependent — masteron's cosmetic contribution is most visible below 12% body fat, where there is minimal subcutaneous water to displace; at higher body fat levels the hardening effect is present but not visually prominent.
- Anti-estrogenic tissue environment without AI over-suppression: drostanolone's anti-estrogenic mechanism is indirect (tissue-level E2 competition) rather than aromatase inhibition; this provides a natural estrogen-buffering effect that reduces (but does not eliminate) the AI requirement from the testosterone propionate component; users often find they need a lower Anastrozole BD dose on Ultrabol cycles than on testosterone-only cycles at the same testosterone dose.
- Nutrient partitioning and lean mass preservation from the trenbolone fraction: trenbolone acetate's exceptionally high AR affinity drives protein synthesis and nitrogen retention even in a caloric deficit; on a pre-contest cut where calories are restricted, the trenbolone component protects against lean tissue catabolism, redirects dietary protein toward muscle protein synthesis, and enhances the visual conditioning process by accelerating fat mobilisation relative to muscle loss.
- Stable androgenic base from the testosterone fraction — libido and mood protection: the testosterone propionate component prevents the libido suppression, fatigue, and mood deterioration that occurs when trenbolone is run without a testosterone base; at 175 mg/week (1 ml EOD), the testosterone dose is sufficient for physiological hormone function without driving significant estrogen load — particularly given drostanolone's concurrent anti-estrogenic effect.
- Fast-onset and fast-exit kinetics from short-ester format: unlike long-ester cutting blends, Ultrabol 150 BD reaches effective blood levels within the first week; cycle effects are active by day 3–5; if the blend is not well tolerated (tren-related night sweats, BP, or prolactin issues), reducing or stopping the compound takes effect within 5–7 days as all three short esters clear; this fast-exit advantage is the primary reason experienced users prefer the propionate/acetate format for a first run with a multi-compound blend.
Who It's For
Ultrabol 150 BD is for experienced AAS users who have already run separate trenbolone and testosterone cycles, understand their individual response to trenbolone (including prolactin management and AI calibration), and are transitioning to a pre-calibrated short-ester cutting blend for pre-contest or recomposition phases. The simultaneous presence of trenbolone acetate makes this a compound requiring prior trenbolone experience — not an entry-level product regardless of the testosterone and masteron components.
The primary scenario where Ultrabol 150 BD is the right choice: a 8–10 week pre-contest cutting phase where the user needs three synergistic cutting compounds in a single EOD injection, wants fast onset and fast PCT clearance from short esters, and has already confirmed their trenbolone response on a previous cycle. The 1:1:1 ratio (50 mg each component per ml) provides a balanced starting point that works well at 1 ml EOD for most experienced users, with scope to increase to 1.5 ml EOD for advanced applications.
Users who should not choose Ultrabol 150 BD: anyone on their first trenbolone cycle (run Trenabol 100 BD acetate separately first to establish dose and tolerance before combining with a blend); users who need to dose individual components at different ratios than 1:1:1 (better served by separate compounds); users above 15% body fat where masteron's cosmetic contribution is limited and the trenbolone side-effect burden outweighs the conditioning benefit; users not yet comfortable with EOD injection schedules.
Ultrabol 150 vs Alternatives
| Compound | Key Differences | Choose Ultrabol 150 BD When | Choose Alternative When |
|---|---|---|---|
| Cut Mix 150 Dragon Pharma (testosterone propionate + trenbolone acetate + drostanolone propionate, 150 mg/ml) | Same three-compound concept (test prop + tren ace + masteron prop) at the same 150 mg/ml concentration; same EOD injection schedule; same PCT timing (3–5 days post-last-injection); both are pre-calibrated short-ester cutting blends; the per-component ratio may differ between manufacturers — Ultrabol 150 BD is 50 mg each; brand and individual manufacturing preferences are the primary differentiator | British Dragon brand preferred; existing cycle uses other BD compounds (testabol, trenabol) and brand consistency is desired | Dragon Pharma brand preferred; existing cycle uses other DP compounds; the per-component ratio in Cut Mix 150 DP better matches the user's target doses |
| Masteron 100 Dragon Pharma + Trenbolone 100 Dragon Pharma separately | Same three compounds but sourced and dosed individually; separate sourcing allows full dose customisation of each component independently (e.g. running 300 mg masteron + 150 mg tren + 200 mg test per week rather than fixed 1:1:1 ratio); separate compounds require more vials and tracking; Ultrabol 150 BD simplifies EOD injections to a single vial; individual compounds are preferred when the target dose ratio differs significantly from 50:50:50 | A balanced 1:1:1 cutting trinity is the target; injection simplicity (one vial, one EOD pin) is preferred; no need to fine-tune component ratios independently | Doses of individual components need to differ from the 1:1:1 ratio (e.g. higher masteron relative to tren, or lower test base); fine-grained dose adjustments mid-cycle are needed; one component (e.g. masteron) needs to be stopped independently of the others |
| Ultrabol Forte 275 British Dragon (same composition, 275 mg/ml) | Identical three-compound composition; Forte delivers 100 mg masteron + 100 mg test prop + 75 mg tren acetate per ml vs Ultrabol 150's 50 mg each; higher concentration means fewer ml per injection for the same weekly dose; Forte is more suitable for experienced users at higher weekly targets; Ultrabol 150 is easier to dose-titrate for first-run with the blend; higher concentration formulations can cause more injection site discomfort (PIP) due to solvent load | First use of this specific blend — easier dose titration at lower ml per injection; weekly target dose is 300–525 mg (achievable at 2–3.5 ml/week of Ultrabol 150); injection comfort preferred over concentration efficiency | Weekly dose target requires more than 3.5 ml of Ultrabol 150 per week (switch to Forte for fewer ml per injection at higher doses); experienced users preferring lower injection volume with higher concentration; Forte's ratio (masteron and test heavier than tren) is preferred over the 1:1:1 of Ultrabol 150 |
Combinations
| Goal | Primary | Support Compounds | Notes |
|---|---|---|---|
| Classic pre-contest — standalone cutting trinity EOD | Ultrabol 150 BD 1 ml EOD (wks 1–8) — 525 mg/wk (masteron 175 + test 175 + tren 175 mg) | Anastrozole BD + Caberlin + Ecosprin 75 mg/day | All three cutting compounds in one EOD pin; Anastrozole BD dosed conservatively against the 175 mg/wk test prop component (masteron's anti-estrogenic effect reduces AI requirement — typically half the dose used on a testosterone-only cycle at the same test dose); Caberlin 0.25 mg twice weekly from day 1 for the tren component; check E2 and prolactin at week 3–4; PCT starts 3–5 days after last injection |
| Enhanced masteron dose — maximum pre-contest hardening | Ultrabol 150 BD 1 ml EOD (wks 1–10) | Mastabol 100 BD (drostanolone propionate) 100 mg EOD additional (wks 1–10) + Anastrozole BD + Caberlin | The extra Mastabol 100 BD injection can be combined into the same EOD pin as Ultrabol 150 BD; total masteron rises to ~525 mg/wk while test and tren stay at 175 mg/wk each; the amplified masteron dose intensifies the hardening and anti-estrogenic tissue effect; Anastrozole BD requirement drops further at higher masteron relative to testosterone; suitable for athletes at sub-12% body fat in the final 8–10 weeks pre-contest; all short esters clear in 3–5 days — PCT as normal |
| Oral finisher — stanozolol in final 4–6 weeks | Ultrabol 150 BD 1 ml EOD (wks 1–10) | Stanabol Tablets BD (stanozolol 10 mg) 40–50 mg/day (wks 5–10) + Anastrozole BD + Caberlin | Ultrabol 150 BD provides the injectable cutting base for the full 10 weeks; Stanabol Tablets BD added in the last 4–6 weeks for additional hardness and vascularity from oral stanozolol; both stanozolol and trenbolone severely suppress HDL — mandatory lipid panel at week 6; do not extend Stanabol BD beyond 6 weeks; stop all compounds simultaneously — stanozolol clears within 2–3 days, all Ultrabol 150 BD esters clear in 3–5 days; begin PCT at day 4–5 post last injection |
| Higher test base — lean recomposition with testosterone top-up | Ultrabol 150 BD 1 ml EOD (wks 1–10) | Testabol Propionate BD 100 mg EOD additional (wks 1–10) + Anastrozole BD + Caberlin | Adding Testabol Propionate BD at 100 mg EOD raises the weekly testosterone dose from 175 mg to ~525 mg while masteron and trenbolone remain at 175 mg/wk each; this shifts the stack toward a higher testosterone:tren ratio suitable for lean recomposition with more muscle volume focus, vs the equal-ratio pre-contest format of standalone Ultrabol 150 BD; the higher testosterone dose increases E2 management requirement — calibrate Anastrozole BD dose at week 3 E2 check; can be combined in the same syringe with Ultrabol 150 BD on EOD injection days |
Side Effects & Management
| Side Effect | Frequency | How to Handle It |
|---|---|---|
| Prolactin elevation from trenbolone fraction | Common; same progestogenic mechanism as all trenbolone products; the 50 mg/ml tren ace component at 175 mg/wk (1 ml EOD) is sufficient to cause prolactin elevation in predisposed users | Caberlin (cabergoline) 0.25 mg twice weekly from the first injection; check prolactin at week 3–4; increase to 0.5 mg twice weekly if above reference range; continue through the first 1–2 weeks of PCT as short esters clear; do not use an AI for prolactin symptoms |
| Estrogen management — reduced AI requirement vs testosterone-only cycles | E2 elevation from the testosterone propionate component (175 mg/wk) is present but partially offset by drostanolone's anti-estrogenic tissue effect; net estrogenic burden is lower than testosterone alone at the same dose; some users do not require AI at 1 ml EOD | Anastrozole BD at a conservative starting dose (0.25 mg EOD or 0.5 mg twice weekly); check E2 at week 3–4 and adjust; avoid over-suppression — crushed E2 on a cutting stack causes joint pain and impairs the already-limited recovery between training sessions; target E2 20–40 pg/mL |
| HDL suppression and lipid disruption | Consistent; all three components suppress HDL to varying degrees; stanozolol addition (if used) compounds this significantly | Baseline lipid panel mandatory; omega-3 4 g/day; mid-cycle lipid check at week 4–5; Atorvastatin 40 mg DP if LDL exceeds 160 mg/dL; avoid combining with oral 17-AA AAS without mandatory lipid monitoring |
| Night sweats and insomnia from trenbolone fraction | Common; proportional to the trenbolone acetate dose (175 mg/wk at 1 ml EOD); at lower doses (0.5 ml EOD = ~87.5 mg tren/wk) significantly less frequent | Cool sleeping environment; dose reduction is the only effective management strategy; because acetate ester clears in 2–3 days, any dose reduction or cycle interruption takes effect quickly — unlike hexa or enanthate where side effects persist longer post-dose-change |
| Blood pressure elevation | Common; driven by hematocrit rise and the testosterone/trenbolone components; masteron does not directly raise BP | Weekly BP self-monitoring; target below 130/80 mmHg; manage E2 with Anastrozole BD; Ecosprin 75 mg/day throughout; Amlip (amlodipine) 5 mg/day if above target |
| Injection site discomfort (PIP) | Common with short-ester propionate compounds; 150 mg/ml is a moderate concentration; rotating sites (glute, quad, delt) and warming the vial before injection reduces PIP | Warm vial in hand for 1–2 minutes before drawing; inject slowly; strict site rotation every EOD injection; PIP severity varies by individual; if consistently severe at 1 ml, reduce to 0.75 ml and consider supplementing from a single-ester vial to reach target dose |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Prolactin | Baseline; week 3–4; post-PCT (4 weeks after completion) | Male reference range; above 20 ng/mL: increase Caberlin to 0.5 mg twice weekly; short-ester tren ace is active quickly — week 3–4 is a reliable early reading for prolactin calibration |
| Estradiol (E2) | Baseline; week 3–4 (AI calibration); post-cycle | Target 20–40 pg/mL on cycle; drostanolone's anti-estrogenic effect means actual E2 with AI may be lower than expected — test before increasing AI dose; over-suppression on a cutting stack causes joint pain and training impairment |
| Lipid panel (HDL, LDL, TG) | Baseline; week 4–5; post-cycle (4–6 weeks after) | HDL above 35 mg/dL; LDL below 130 mg/dL; all three compounds suppress HDL; post-cycle lipid recovery expected within 4–8 weeks |
| Hematocrit & CBC | Baseline; week 4–5 | Hematocrit below 52%; Ecosprin 75 mg/day when above 48% |
| Blood pressure | Baseline; weekly self-monitoring | Below 130/80 mmHg; address E2 and hematocrit first before antihypertensive; Amlip 5 mg/day if persistent |
| LH + FSH | Baseline; post-PCT (4 weeks after completion) | Post-PCT return to pre-cycle baseline; all three esters clear within 5–7 days; SERM therapy is active within days of starting; verify HPG recovery at 4 weeks post-PCT |
| Total testosterone | Baseline; post-PCT (4 weeks after completion) | Return to pre-cycle baseline; below 300 ng/dL at 6 weeks post-PCT indicates incomplete HPG recovery |
PCT
All three components of Ultrabol 150 BD carry short esters (propionate: ~2–3 day half-life; acetate: ~2–3 day half-life). After the last EOD injection, all three active substances clear within 5–7 days. Begin SERM therapy 3–5 days after the last injection — this is the primary PCT advantage of the short-ester blend format over long-ester cutting compounds.
Standard 4-week PCT protocol:
- Weeks 1–2: Tamoxifen BD 40 mg/day + Clomiphene BD 50 mg/day
- Weeks 3–4: Tamoxifen BD 20 mg/day + Clomiphene BD 25 mg/day
HCG: For 8–10 week cycles, run HCG 5,000 IU Dragon Pharma at 2,500 IU on two days in the clearance window (days 1–3 post last injection), completing the last HCG dose at least 5 days before the first SERM dose. Continue Caberlin 0.25 mg twice weekly through the first 1–2 weeks of PCT as trenbolone prolactin activity resolves. The fast ester clearance means Caberlin can typically be stopped by week 2 of PCT (sooner than with long-ester trenbolone blends).
Practical Summary
- Confirmed prior trenbolone tolerance is the prerequisite: the trenbolone acetate component of Ultrabol 150 BD is the compound requiring prior experience; run Trenabol 100 BD (acetate solo) first to establish your individual response to trenbolone before combining it with masteron and testosterone in a single-vial blend.
- Start AI conservatively — masteron reduces the AI requirement: drostanolone propionate at 175 mg/wk has a meaningful anti-estrogenic tissue effect; do not dose Anastrozole BD against the testosterone propionate component as if masteron were absent; start at 0.25 mg EOD or 0.5 mg twice weekly and calibrate from the week 3–4 E2 bloodwork reading.
- Cabergoline from day 1 — not when symptoms appear: the trenbolone fraction is active within 48 hours; start Caberlin 0.25 mg twice weekly with the first injection; checking prolactin at week 3–4 confirms the dose is adequate; do not wait for libido or erectile symptoms before starting cabergoline.
- Fast-exit advantage: use it if side effects develop: all three propionate/acetate esters clear within 5–7 days of stopping; if night sweats, cardiovascular stress, or prolactin-driven effects become unmanageable, stopping the cycle resolves blood levels within one week — unlike hexa or enanthate formats where side effects persist for 2–3 weeks post-last-injection.
- 1 ml EOD × 8 weeks = 28 ml ≈ 3 vials; 10 weeks = 35 ml ≈ 4 vials: secure full cycle supply before starting; do not begin a cycle without all vials on hand; dose math at 0.75 ml EOD (21 ml/8 wks) works from 3 vials if conserving supply.
- Body fat below 15% to get full value from the masteron fraction: drostanolone propionate's hardening and cosmetic effect requires low subcutaneous fat to be visible; if body fat is above 15%, the trenbolone and testosterone components remain effective but the masteron contribution is largely wasted; plan the Ultrabol 150 BD cycle to run in the later stages of a cut, not from a high body fat baseline.
Ultrabol 150 BD from Steroid Warehouse is the pre-calibrated short-ester cutting trinity for experienced athletes who want masteron, testosterone, and trenbolone in a single EOD injection with the full fast-clearance flexibility of propionate and acetate esters. At sub-15% body fat in a structured 8–10 week pre-contest phase, the three-compound synergy — testosterone's androgenic base, masteron's hardening and anti-estrogenic effect, and trenbolone's nutrient partitioning and vascularity — produces the combined conditioning outcome that makes this blend a consistently referenced choice among competitive athletes preparing for stage or photo conditions.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin S et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, especially when supraphysiologic testosterone was combined with resistance training | Bhasin S, et al. (1996) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations across anabolic-androgenic steroid use in sport | Hartgens F & Kuipers H (2004) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on anabolic-androgenic steroids including testosterone derivatives and injectable esterified AAS; covers androgen receptor mechanism, HPG-axis suppression, adverse effects, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone biosynthesis, androgen receptor signaling, HPG-axis regulation, aromatization, synthetic androgen pharmacology, and endocrine suppression from exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| The Lancet / PubMed | Basaria S 2014 — clinical review of male hypogonadism; covers testosterone physiology, causes of androgen deficiency, diagnostic evaluation, testosterone therapy, treatment monitoring, and safety considerations relevant to low or suppressed endogenous testosterone states | Basaria S (2014) ↗ |
What is Ultrabol 150?
Ultrabol 150 is an injectable anabolic steroid blend (Drostanolone Propionate, Testosterone Propionate, Trenbolone Acetate) for lean muscle and definition; see What is Ultrabol 150. It's potent—consult professionals for safe use.
What does Ultrabol 150 do?
It promotes lean muscle, strength, and fat loss; see What Does Ultrabol 150 Do. It enhances physique—monitor with labs.
Are Ultrabol 150 safe?
It can be safe with responsible use, but risks include testosterone suppression and cardiovascular strain; see Are Ultrabol 150 Safe. Consult professionals for oversight.
How do I take Ultrabol 150?
150-450 mg/week, injected EOD; see How to Take Ultrabol 150. Start low—consult professionals for dosing.
How to cycle Ultrabol 150?
6-8 weeks, 150-450 mg/week, PCT after 3-5 days; see How to Cycle Ultrabol 150. Stack with anabolics—consult professionals.
How does Ultrabol 150 work?
Ultrabol 150 works through the combined effects of its active ingredients, promoting anabolic activity, protein synthesis, nitrogen retention, and recovery support to help optimize muscle development and performance.
How long does it take to notice effects from Ultrabol 150?
The onset of effects depends on the specific compounds and esters included in the formulation, but users commonly report gradual improvements in strength, recovery, muscle fullness, and physique appearance over several weeks.
What are the main benefits of Ultrabol 150?
Commonly reported benefits include increased lean muscle mass, enhanced strength, improved recovery, support for body recomposition, and overall physique conditioning.
Related Products
- Enhances muscle definition and hardness.
- Promotes lean muscle retention during cutting.
- Reduces estrogen-related water retention.
- Delivers rapid anabolic and anti-estrogenic effects.
- Promotes muscle hardness and definition.
- Enhances strength for intense training.
- Supports fat loss for a vascular physique.
- Delivers dry gains with no water retention.
